Axsome Therapeutics (AXSM) Tops Q2 EPS by 9c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.97), $0.09 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $150.04 million versus the consensus estimate of $139.31 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates